

# European Association of NeuroOncology Magazine

Neurology · Neurosurgery · Medical Oncology · Radiotherapy · Paediatric Neuro-  
oncology · Neuropathology · Neuroradiology · Neuroimaging · Nursing · Patient Issues

## Interorganizational Collaboration between EANO and SNO in 2012

Aldape K, Grisold W, Haynes JC

Soffietti R

*European Association of  
NeuroOncology Magazine 2012; 2 (2)*

107

Homepage:

[www.kup.at/  
journals/eano/index.html](http://www.kup.at/journals/eano/index.html)

Online Database Featuring  
Author, Key Word and  
Full-Text Search



THE EUROPEAN ASSOCIATION OF  
NEUROONCOLOGY

Member of the 

# Interorganizational Collaboration between EANO and SNO in 2012



Ken Aldape<sup>1</sup>, Wolfgang Grisold<sup>2</sup>, J Charles Haynes<sup>3</sup>, Riccardo Soffietti<sup>4</sup>

<sup>1</sup>Dept of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; <sup>2</sup>Dept of Neurology, Kaiser-Franz-Josef-Spital, Vienna, Austria; <sup>3</sup>Society for Neuro-Oncology, Bellaire, TX, USA; <sup>4</sup>Division of Neuro-Oncology, Dept of Neuroscience, University and San Giovanni Battista Hospital, Turin, Italy

As part of on-going efforts to forge a closer relationship between the European Association for Neuro-Oncology (EANO) and the US-based Society for Neuro-Oncology (SNO), each organization will feature reciprocal “meet-the-experts” sessions at their respective meetings this autumn.

The EANO meeting in Marseille in September will feature a session chaired by Ken Aldape (Houston) and Riccardo Soffietti (Turin) entitled, “Update in Neuro-Oncology”. This session will cover the following topics:

- What is the right place for bevacizumab: at recurrence or in upfront treatment?  
*Susan Chang, San Francisco*
- Biology of resistance to antiangiogenic therapies  
*Michael Weller, Zurich*
- Is there a role for dose-dense temozolomide?  
*Mark Gilbert, Houston*
- Outcome predictors in low-grade and anaplastic gliomas  
*Wolfgang Wick, Heidelberg*

Correspondingly, the SNO meeting in Washington, DC, in November will feature a special joint EANO/SNO “meet-the-experts” session moderated by Riccardo Soffietti and Mark Gilbert entitled, “From Guidelines to New Trials in Low-Grade Gliomas: The American and European Views”. The session will cover the following topics:

- What is the role of awake surgery?  
*Mitchel Berger, San Francisco, and Hugues Duffau, Montpellier*
- What is the role of chemotherapy?  
*David Schiff, Charlottesville, and Riccardo Soffietti, Turin*

In addition to the “meet-the-experts” sessions noted above, this year the leadership of both organizations established a reciprocal travel scholarship to allow young investigators to travel to each other’s meetings. A combined EANO/SNO committee graded the submitted abstracts, selecting 2 from each organization.

From EANO:

- *Florien Boele, Amsterdam*: Augmenting quality of life and mastery of informal caregivers of high-grade glioma patients: A randomized controlled trial
- *Anna Berghoff, Vienna*: Signal intensity in preoperative diffusion-weighted imaging correlates with survival times in patients with single brain metastasis

From SNO:

- *Justin Lathia, Cleveland*: Identification of a glioblastoma stem cell-specific communication mechanism that drives malignancy and is amenable for therapeutic targeting
- *Sameer Agnihotri, Toronto*: Elucidation of DNA repair signatures that confer resistance to temozolomide and poor survival in patients

Travel scholarship recipients will present their research as a guest of the host organization during the upcoming meetings. The leadership of both EANO and SNO look forward to exploring additional ways to expand interorganizational collaboration in future.

**Correspondence to:**

*J Charles Haynes, JD  
Society for Neuro-Oncology  
4617 Birch Street  
Bellaire, TX 77401-5509, USA  
E-mail: chas@soc-neuro-onc.org*